부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
Company news | Contera Pharma, a subsidiary of Bukwang, has partnership wit..
-to design RNA therapeutics for rare diseases using x AI technologyContera Pharm..
2021.07.08
R&D news | Bukwang concluded the patient recruitment for the clinical ..
Bukwang Pharmaceutical Co., Ltd. announced that they concluded patient recruitme..
2021.06.11
R&D news | Bukwang confirmed Levovir showed tendency of reducing virus..
Bukwang Pharmaceutical Co., Ltd. announced the topline result of CLV-201, the Ph..
2021.05.12
R&D news | Bukwang initiates dosing of JM-010 in the US phase 2 study
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been admini..
2021.05.03
R&D news | Bukwang Pharmaceutical increased the number of patients for ..
Bukwang increased the number of patients from 40 to 80Bukwang announced that the..
2021.04.13
R&D news | Bukwang received US FDA approval for phase 2 clinical study ..
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that they received US FDA..
2021.02.05
1
2
3
4
5